Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05061797 · ClinicalTrials.gov registry record · NA

A Study to Examine the Effect of a Thermogenic Energy Drink in Healthy Adults

A NA study of Metabolism, sponsored by Rowdy Energy.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05061797: Completed NA study of Metabolism, sponsored by Rowdy Energy.

NCT05061797 is a NA study of Metabolism that has completed, run by Rowdy Energy. The registered enrollment target is 30 participants, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05061797, a NA study of Metabolism, has completed, sponsored by Rowdy Energy.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is intended to examine the acute thermogenic effects of the active study product (energy drink), in healthy adults.

Primary Outcome

The quantified Thermogenic Impact of the ASP as measured from Resting Energy Expenditure testing with human participants following consumption of the ASP Thermogenic Energy Beverage. This is done via the difference in the net-incremental area under the curve (AUC) for the ASP Thermogenic Beverage vs. the Placebo. A larger difference in REE between the ASP Thermogenic Beverage and the Placebo indicates a greater Thermogenic (calorie expending) effect from the ASP Thermogenic Beverage.

Conditions Studied

Metabolism

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Thermogenic Energy Drink - Active Study Product Formula

Study Locations (1)

Illinois

  • Biofortis Clinical Research - Addison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-08-23
Est. Completion 2021-11-16
Phase NA
Rowdy Energy

1 total trials

What the finished NCT05061797 record still lists

NCT05061797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Metabolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05061797 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05061797 about?

NCT05061797 is a clinical study titled "A Study to Examine the Effect of a Thermogenic Energy Drink in Healthy Adults". This study is intended to examine the acute thermogenic effects of the active study product (energy drink), in healthy adults.

What is the current status of trial NCT05061797?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-08-23. Estimated completion is 2021-11-16.

What conditions does trial NCT05061797 study?

This clinical trial studies the following conditions: Metabolism.

What interventions are being tested in trial NCT05061797?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Thermogenic Energy Drink - Active Study Product Formula (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05061797?

This trial is sponsored by Rowdy Energy, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05061797 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05061797's enrollment target sits among peer trials

30 9th of 19 higher than 10 of 19 other Metabolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05061797, the US trial registry maintained by the National Library of Medicine. NCT05061797 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.